Phenotypes Associated with This Genotype

Genotype
MGI:5528704

• Allelic Composition: Tnfaip3^tm4.1Ama/Tnfaip3^tm4.1Ama
• Genetic Background: C57BL/6J-Tnfaip3^tm4.1Ama

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

increased susceptibility to induced colitis ( J:203160 )

• DSS treated mice exhibit increased clinical features compared with wild-type mice

enlarged spleen ( J:203160 )

• gradually at 6 months

myeloid hyperplasia ( J:203160 )

• at 6 months

increased B cell number ( J:203160 )

• at 6 months

increased CD4-positive, alpha-beta T cell number ( J:203160 )

• at 6 months

increased CD8-positive, alpha-beta T cell number ( J:203160 )

• at 6 months

abnormal chemokine secretion ( J:203160 )

• mice treated with TNF exhibit reduced serum MCP-1/CCL2 compared with wild-type mice

decreased interleukin-6 secretion ( J:203160 )

• in mice treated with TNF

digestive/alimentary system

increased susceptibility to induced colitis ( J:203160 )

• DSS treated mice exhibit increased clinical features compared with wild-type mice

growth/size/body

growth/size/body region phenotype ( J:203160 )

N • unlike mice homozygous for Tnfaip3^tm1Ama, mice do not develop perinatal cachaxia

enlarged spleen ( J:203160 )

• gradually at 6 months

hematopoietic system

enlarged spleen ( J:203160 )

• gradually at 6 months

myeloid hyperplasia ( J:203160 )

• at 6 months

increased B cell number ( J:203160 )

• at 6 months

increased CD4-positive, alpha-beta T cell number ( J:203160 )

• at 6 months

increased CD8-positive, alpha-beta T cell number ( J:203160 )

• at 6 months